Insulin-like Growth Factor-I (IGF-I) Serum Concentrations in Depressed Patients: Relationship to Saliva Cortisol and Changes during Antidepressant Treatment

B. Weber-Hamann; W. F. Blum; J. Kratzsch; M. Gilles; I. Heuser; M. Deuschle

doi:10.1055/s-0028-1085442

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2009; 42(1): 23-28
DOI: 10.1055/s-0028-1085442

Original Paper

Insulin-like Growth Factor-I (IGF-I) Serum Concentrations in Depressed Patients: Relationship to Saliva Cortisol and Changes during Antidepressant Treatment

B. Weber-Hamann¹ , W. F. Blum² ^, ³ , J. Kratzsch⁴ , M. Gilles¹ , I. Heuser¹ ^, ⁵ , M. Deuschle¹

¹Central Institute of Mental Health, Mannheim, Germany
²Lilly Research Laboratories, Eli Lilly & Co., Bad Homburg, Germany
³University Children's Hospital, Giessen, Germany
⁴Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Germany
⁵Department of Psychiatry and Psychotherapy, Charité, Campus Benjamin Franklin, Berlin, Germany

Abstract

Introduction: The present study was designed to test the hypothesis that total and free insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients are related to hypothalamus-pituitary-adrenal (HPA) system activity and show a longitudinal decline in patients responding to treatment as well as to declining HPA system activity.

Methods: We measured total and free IGF-I as well as IGF-binding protein-3 in 77 depressed patients after wash-out of pre-medication and again after 28 or 35 days of treatment with paroxetine or amitriptyline.

Results: Total but not free IGF-I serum concentrations are related to saliva cortisol concentrations in drug-free depressed patients. In responders to both amitriptyline and paroxetine, total IGF-I serum concentrations declined during treatment.

Discussion: Our findings show IGF-I to be related to HPA system activity and to decline in responders to treatment while serum concentrations of the biologically active free IGF-I are neither related to HPA system activity nor do they change during the course of treatment. Our data do not support the hypothesis that free IGF-I may play a major role in physical disturbances in depressed patients.

Full Text

References

1 Bang P, Degerblad M, Thoren M. et al . Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome. Acta Endocrinol (Copenh). 1993; 128 397-404
2 Blum WF, Albertsson-Wikland K, Rosberg S. et al . Serum levels of insulin-like growth factor 1 and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab. 1993; 76 1610-1616
3 Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 1994; 4 ((Suppl 1)) 11-19
4 Blum WF, Ranke MB, Kietzmann K. et al . A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990; 70 1292-1298
5 Bunn RC, Fowlkes JL. Insulin-like growth factor binding protein proteolysis. Trends Endocrin Metab. 2003; 14 176-181
6 Contreras F, Navarro MA, Menchon JM. Growth hormone response to growth hormone releasing hormone in nondelusional and delusional depression and healthy controls. Psychological Medicine. 1996; 26 301-307
7 Deijen JB, Boer H de, Veen EA van der. Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology. 1998; 23 45-55
8 Deuschle M, Blum WF, Strasburger CJ. et al . Insulin-like growth factor-I plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997; 22 493-503
9 Deuschle M, Hamann B, Meichel C. et al . Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. J Clin Psychopharmacol. 2003; 23 201-205
10 Deuschle M, Krumm B, Bindeballe N. et al . Open-label non-randomized versus double-blind randomized antidepressive treatment: what are the advantages of clinical decision over randomization. Pharmacopsychiatry. 2004; 37 299-302
11 Deuschle M, Luppa P, Hamann B. et al . Increased concentration of corticostreroid-binding globulin due to antidepressant treatment with amitriptyline, but not paroxetine. J Psychiatr Res. 2003; 37 85-87
12 Franz B, Buysse DJ, Cherry CR. et al . Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatric Res. 1999; 33 121-127
13 Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon?. Biol Psychiatry. 2004; 56 146-150
14 Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005; 1037 204-208
15 Janssen JA, Stolk RP, Pols HA. et al . Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. J Clin Endocrinol Metab. 1998; 48 471-478
16 Janssen JA, Jacobs ML, Derkx FH. et al . Free and total insulin-like growth factor (IGF-I), IGF binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997; 82 2809-2815
17 Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16 3-34
18 Kopf D, Wesphal S, Luley CW. et al . Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism and antidepressant treatment. J Clin Psychopharmacol. 2004; 24 527-531
19 LeRoith D. The insulin-like growth factor system. Experimental Diab Res. 2003; 4 205-212
20 Lesch KP, Rupprecht R, Müller U. et al . Insulin-like growth factor I in depressed patients and controls. Acta Psychiatrica Scandinavica. 1988; 78 684-688
21 Lesch KP, Laux G, Erb A. et al . Growth hormone (GH) and prolactin responses after GH-releasing hormone in major depressive disorder: relationship to somatomedin C levels and dexamethasone suppressibility of cortisol. Psychoneuroendocrinology. 1988; 13 255-263
22 Magiakou MA, Mastorakos G, Gomez MT. et al . Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J Clin Endocrinol Metab. 1994; 78 131-137
23 Mahajan T, Crown A, Checkley S. et al . Atypical depression in growth hormone deficient adults, and the beneficial effects of growth hormone treatment on depression and quality of life. Eur J Endocrinology. 2004; 151 325-332
24 Malberg JE, Platt B, Rizzo SJ. et al . Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007 Mar 7; , (epub ahead of print)
25 MacMillan CV, Bradley C, Gibney J. et al . Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency. Clin Endocrinology. 2003; 59 467-475
26 Nam SY, Lee EJ, Kim KR. et al . Effect of obesity on total and free insulin-like growth factor (IGF)-1 and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997; 21 355-359
27 Nass R, Thorner MO. Impact of GH-cortisol ratio on the age-dependent changes in body composition. Growth Horm IGF Res. 2002; 12 147-161
28 Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab. 1998; 83 1853-1859
29 Rupprecht R, Rupprecht C, Rupprecht M. et al . Effect of glucocorticoids on the regulation of the hypothalamic-pituitary-somatotropic system in depression. J Affective Disord. 1989; 17 9-16
30 Schneider HJ, Pagotto U, Stalla GK. Central effects of somatotropic system. Eur J Endocrinology. 2003; 149 377-392
31 Siever LJ, Trestman RL, Coccaro EF. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology. 1992; 6 165-177
32 Smink JJ, Gresnigt MG, Hamers N. et al . Short-term glucocorticoid treatment of prepubertal mice decreases growth and IGF-I expression in the growth plate. J Endocrinol. 2003; 177 381-388
33 Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res. 2001; 56 ((Suppl 1)) 1-6
34 Takahashi M, Sawayama E, Sawayama T. et al . Reversible paroxetine-induced symptomatic hypothyroidism. Pharmacopsychiatry. 2007; 40 201-202
35 Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrinology Review. 1994; 15 80-101
36 Tichomirowa MA, Keck ME, Schneider HJ. et al . Endocrine disturbances in depression. J Endocrinol Invest. 2005; 28 89-99
37 Wajchenberg BL, Liberman B, Giannella ND. et al . Growth hormone axis in Cushing's syndrome. Horm Res. 1996; 45 99-107
38 Wakeno M, Okugawa G, Takekita Y. et al . Delirium associated with paroxetine in an elderly depressive patient: a case report. Pharmacopsychiatry. 2007; 40 199-200
39 Watson S, Porter RJ, Young AH. Effect of hydrocortisone on the pituitary response to growth hormone releasing hormone. Psychopharmacology. 2000; 152 40-46
40 Weber-Hamann B, Hentschel F, Kniest A. et al . Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med. 2002; 64 274-277
41 Zenker S, Haverkamp F, Klingmüller D. Growth hormone deficiency in pituitary disease: relationship to depression, apathy and somatic complaints. Eur J Endocrinology. 2002; 147 165-171
42 Zhou X, Loke KY, Pillai CC. et al . IGFs and IGF- binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH. Eur J Endocrinol. 2001; 144 237-243

Correspondence

B. Weber-HamannMD

Central Institute of Mental Health

J5

68159 Mannheim

Germany

Phone: +49/621/1703 23 21

Fax: +49/621/1703 23 25

Email: bettina.hamann@zi-mannheim.de